文献速递乳腺癌

体细胞驱动基因改变与绝经后HR阳性HER2阴性早期乳腺癌预后关联:BIG 1-98试验二次分析

Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2018-01-01

该研究基于BIG 1-98随机试验中764例绝经后HR阳性/HER2阴性早期乳腺癌患者,对538例成功测序样本分析驱动基因改变与远处复发及内分泌治疗获益的关系。中位随访8.1年,PIK3CA突变与远处复发风险降低相关,11q13和8p11扩增及驱动改变数目增多与风险升高相关,PIK3CA激酶或螺旋域突变患者从来曲唑获益更大。

要点

  • PIK3CA突变最常见(49%),与远处复发风险降低显著相关(HR 0.57)。
  • 11q13和8p11扩增在多变量分析中仍为远处复发的显著预测因子。
  • PIK3CA激酶或螺旋域突变患者从来曲唑相比他莫昔芬的获益显著更大。

核心结论

  • 在绝经后ER+/HER2-早期乳腺癌中,11q13和8p11扩增与远处复发风险增加显著相关,PIK3CA突变可预测来曲唑获益更大。

研究设计与样本

  • BIG 1-98随机临床试验的二次分析,纳入764例绝经后HR+/HER2-可手术浸润性乳腺癌患者,对原发肿瘤行二代测序,538例成功测序。

主要发现

  • PIK3CA突变是最常见驱动改变(49%),与远处复发风险降低显著相关(HR 0.57;95%CI 0.38-0.85;P=.006)。
  • TP53突变(HR 1.92;95%CI 1.21-3.04;P=.006)、11q13扩增(HR 2.14;95%CI 1.36-3.37;P=.001)、8p11扩增(HR 3.02;95%CI 1.88-4.84;P<.001)及驱动改变数目增多(每增加一个改变HR 1.18;95%CI 1.11-1.25;P<.001)与远处复发风险升高显著相关。
  • 多变量分析中11q13和8p11扩增仍为显著预测因子,PIK3CA和TP53突变则不显著。
  • 携带PIK3CA激酶或螺旋域突变的肿瘤患者从来曲唑相比他莫昔芬的获益显著大于无此类突变者(交互作用P=.002)。

临床怎么用

  • 基于DNA的分类可能有助于该人群的辅助治疗决策。
  • PIK3CA激酶或螺旋域突变或可提示来曲唑相比他莫昔芬的更大获益。

局限性

  • 仅764例样本中538例成功测序,样本量有限。
  • 为二次分析,需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: A range of somatic driver alterations has been described in estrogen receptor-positive, HER2-negative (ER+/HER2-) early breast cancer (BC); however, the clinical relevance is unknown. OBJECTIVE: To investigate associations of driver alterations with prognosis and the role of PIK3CA mutations in prediction of benefit associated with endocrine therapy in postmenopausal patients with ER+/HER2- early BC treated with tamoxifen or letrozole. DESIGN, SETTING, AND PARTICIPANTS: The Breast International Group (BIG) 1-98 trial randomized 8010 postmenopausal patients with hormone receptor-positive, operable, invasive BC to monotherapy with letrozole, tamoxifen, or a sequential strategy for 5 years. Driver alterations were characterized using next-generation sequencing in primary tumors from a subset of 764 patients from 7329 eligible patients with ER+/HER2- BC, with 841 distant recurrences after a median of 8.1 years of follow-up. To correct for the oversampling of distant recurrences, weighted analysis methods were used. This analysis was conducted from April 4, 2016, to November 30, 2016. MAIN OUTCOMES AND MEASURES: The prevalence of driver alterations, associations with clinicopathologic factors, distant recurrence-free interval, and treatment interactions were analyzed. Multivariable analyses were performed to adjust for clinicopathologic factors. RESULTS: Of 764 samples, 538 (70.4%), including 140 distant recurrence events, were successfully sequenced. Nineteen driver alterations were observed with 5% or greater frequency, with a mean of 4 alterations (range, 0-15) per tumor. PIK3CA mutations were the most common (49%) and were significantly associated with reduction in the risk for distant recurrence (hazard ratio [HR], 0.57; 95% CI, 0.38-0.85; P = .006). TP53 mutations (HR, 1.92; 95% CI, 1.21-3.04; P = .006), amplifications on 11q13 (HR, 2.14; 95% CI, 1.36-3.37; P = .001) and 8p11 (HR, 3.02; 95% CI, 1.88-4.84; P < .001), and increasing number of driver alterations (HR per additional alteration, 1.18; 95% CI, 1.11-1.25; P < .001) were associated with significantly greater risk. Amplifications on 11q13 and 8p11 remained significant predictors in multivariable analysis, but not PIK3CA and TP53 mutations. Patients with tumors harboring kinase or helical domain PIK3CA mutations derived significantly greater benefit from letrozole over tamoxifen than patients whose tumors did not (P interaction = .002). CONCLUSIONS AND RELEVANCE: In ER+/HER2- postmenopausal, early-stage BC, amplifications on 11q13 and 8p11 were significantly associated with increased risk for distant recurrence and PIK3CA mutations were predictive of greater magnitude of benefit from letrozole. With these findings, DNA-based classification may aid adjuvant treatment decision making in this setting. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00004205.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Luen SJ, Asher R, Lee CK, et al. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial. JAMA Oncol. 2018. PMID: 29902286. doi:10.1001/jamaoncol.2018.1778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。